Pepper Pike, OH, United States of America

Liraz Levi

This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Celloram Inc.. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Liraz Levi: Innovator in Fatty Acid Metabolism

Introduction

Liraz Levi is a notable inventor based in Pepper Pike, OH (US). He has made significant contributions to the field of pharmaceutical compositions, particularly in the area of fatty acid metabolism. His innovative work focuses on developing compounds that can inhibit specific proteins related to various diseases.

Latest Patents

Liraz Levi holds 1 patent for his invention titled "FABP4/5 inhibitors, methods of use and methods of making." This patent discloses compounds that inhibit FABP4 and FABP5, which are crucial in treating diseases associated with fatty acid metabolism, including cancer. The patent also outlines methods for preparing these compounds, showcasing Levi's commitment to advancing medical science.

Career Highlights

Liraz Levi is currently associated with Celloram Inc., where he continues to work on innovative solutions in the pharmaceutical industry. His research and development efforts are aimed at creating effective treatments that can improve patient outcomes.

Collaborations

Liraz collaborates with talented individuals such as Seunghwan Lim and Elizabeth Meyers, who contribute to his projects and research initiatives. Their combined expertise enhances the potential for groundbreaking discoveries in their field.

Conclusion

Liraz Levi's work in developing FABP4 and FABP5 inhibitors represents a significant advancement in the treatment of diseases related to fatty acid metabolism. His contributions to the pharmaceutical industry are noteworthy and reflect his dedication to innovation and research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…